TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30180087

Group type: EXPERIMENTAL
Intervention: Glutamate injection (1 mol/L or 0.25 mol/L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation (pressure applied to the masseter muscle with 4 different forces: 0.5, 1, 2, and 4 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Painful stimulus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intensity of stimulus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RS centre-of-gravity location
Number of subjects: 60
Study: 27116682

Group type: EXPERIMENTAL
Intervention: γ-tACS
Number of subjects: 10

Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 24507766

Group type: EXPERIMENTAL
Intervention: Radiation therapy with a mean dose to the whole and inferior rectum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Radiation therapy with a median volume of rectum treated to ≥70 Gy (V70)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low (V25-V40), intermediate (V50-V60), and high (V70-V80) doses to the inferior rectum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Highest dose (V80) to the mid-rectum
Number of subjects: 90
Study: 23139250

Group type: EXPERIMENTAL
Intervention: Baseline serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Quartile models of serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations
Number of subjects: 1101
Study: 20336077

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 50

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 50
Study: 18759650

Group type: EXPERIMENTAL
Intervention: Sertraline (n = 13)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 22
Study: 15925644

Group type: EXPERIMENTAL
Intervention: Trait adjectives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional and physiological adjectives
Number of subjects: 0
Study: 12968980

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegaserod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alosetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laxatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticholinergic and antispasmodic agents
Number of subjects: 0
Study: 10579482

Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg dextromethorphan
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg dextromethorphan
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.05 mg/kg dextromethorphan
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.15 mg/kg dextromethorphan
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3 mg/kg dextromethorphan
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30 mg dextromethorphan
Number of subjects: 40
Study: 7574017

Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + propofol infusion (75‐160 micrograms.kg‐1.min‐1 IV)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + sevoflurane (1%‐2% end‐tidal)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sevoflurane (1%‐4% end‐tidal) + nitrous oxide 60% in oxygen
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 146
Study: 1817766

Group type: EXPERIMENTAL
Intervention: Class 1C antiarrhythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatments (catheter ablation and surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Class 1A antiarrhythmic drugs (disopyramide or quinidine)
Number of subjects: 0
Study: 6271841

Group type: EXPERIMENTAL
Intervention: Topical delta 9-tetrahydrocannabinol (THC) in light mineral oil vehicles (0.05% and 0.1% solutions)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Light mineral oil vehicle
Number of subjects: 6
Study: 31164169

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg oral, delivered as a take-home medication for 12 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo, matched to NAC, delivered as a take-home medication for 12 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 29801063

Group type: EXPERIMENTAL
Intervention: IAI monotherapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: IAI/PDT
Number of subjects: 318
Study: 27497418

Group type: EXPERIMENTAL
Intervention: Homeopathy (Agraphis nutans 5CH, Thuya Occidentalis 5CH, Kalium muriaticum 9CH, Arsenicum iodatum)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 25252192

Group type: EXPERIMENTAL
Intervention: mpHBV (1 mL intramuscular dose containing 40 μg HBsAg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Licensed hepatitis B vaccine (1 mL intramuscular dose as two injections, each containing 20 μg HBsAg; total 40 μg HBsAg)
Number of subjects: 276
Study: 22762143

Group type: EXPERIMENTAL
Intervention: LAM+DNA vaccine
Number of subjects: 39

Group type: COMPARATOR
Intervention: LAM monotherapy
Number of subjects: 39
Study: 20054409

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) treatment with leuprolide acetate (3.75 mg) subcutaneously every 4 weeks during chemotherapy
Number of subjects: 22
Study: 17606657

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Quetiapine (100-800 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-4 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 400
Study: 16053780

Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels measured by rapid immunofluorescence assay
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels in patients with left ventricular end-diastolic diameter (LVEDD) ≥ 60 mm
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels in cardiogenic dyspnea group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Correlation of BNP with hemodynamic parameters (PCWP, MPAP, RAP)
Number of subjects: 117
Study: 12115174

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab every 8 weeks
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Higher trough serum concentrations of infliximab
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Decreasing dosing interval from 8 weeks to 6 weeks
Number of subjects: 428
Study: 11579074

Group type: EXPERIMENTAL
Intervention: Computerised cognitive tests (CogState) - SRT test
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-injured players (matched controls)
Number of subjects: 240
Study: 9834004

Group type: EXPERIMENTAL
Intervention: Generic carbamazepine formulations
Number of subjects: 18

Group type: COMPARATOR
Intervention: Innovator carbamazepine formulation
Number of subjects: 18
Study: 7720497

Group type: EXPERIMENTAL
Intervention: LAK/IL-2 plus Lycium Barbarum polysaccharides (LBP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: LAK/IL-2
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LAK/IL-2 plus LBP
Number of subjects: 75
Study: 2557513

Group type: EXPERIMENTAL
Intervention: Intravenous sodium diethyldithiocarbamate (DTC)
Number of subjects: 0
Study: 336378

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acebutolol 1200 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31729607

Group type: EXPERIMENTAL
Intervention: Buccal mucosal-advancement flap
Number of subjects: 150

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Secondary closure
Number of subjects: 150
Study: 31060374

Group type: EXPERIMENTAL
Intervention: Esmolol (β1‐AR blocker)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esmolol + Hypoxia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5050 m (high altitude)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normalized Spo2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esmolol + Normalized Spo2
Number of subjects: 12
Study: 27533115

Group type: EXPERIMENTAL
Intervention: Intraumbilical amino acids and glucose supplementation (10% of feto‐placental blood volume/day) via a perinatal port system
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intraumbilical amino acids and glucose supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14
Study: 26712287

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%, 1 mL/kg for caudal epidural block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg and ketamine 0.3 mg/kg
Number of subjects: 90
Study: 24280465

Group type: EXPERIMENTAL
Intervention: Tai chi Qigong
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 206
Study: 21885498

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 19358697

Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mephaquin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mefloquina AC Farma
Number of subjects: 39
Study: 16423668

Group type: EXPERIMENTAL
Intervention: IV contrast with standard TVI settings
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IV contrast with increased TVI line density
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline (no contrast)
Number of subjects: 40
Study: 15578395

Group type: EXPERIMENTAL
Intervention: Whole-blood analysis for HCV RNA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose treatment with IFN (10 MU every 2 days) and ribavirin (1-1.2 g/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Serum and plasma specimens
Number of subjects: 56
Study: 11410923

Group type: EXPERIMENTAL
Intervention: Multi-MUP analysis using mean values of MUP parameters
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Multi-MUP analysis using outliers of MUP parameters
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of MUP parameters
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normative data from 64 controls
Number of subjects: 56
Study: 9400771

Group type: EXPERIMENTAL
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + adjuvant treatment (AT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for fewer than 6 cycles
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + AT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemoreduction alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (AT)
Number of subjects: 32
Study: 7688335

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 29
Study: 3472467

Group type: EXPERIMENTAL
Intervention: Prostaglandin gel cervical ripening followed by aggressive induction of labor and delivery
Number of subjects: 302

Group type: COMPARATOR
Intervention: Antepartum fetal testing
Number of subjects: 302
Study: 30759291

Group type: EXPERIMENTAL
Intervention: Waterjet dissection of the inferior hypogastric plexus (IHP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional blunt dissection of the inferior hypogastric plexus (IHP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (traditional blunt dissection)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups (waterjet and traditional dissection)
Number of subjects: 160
Study: 26523442

Group type: EXPERIMENTAL
Intervention: 38 Gy RBE in 5 treatments (hypofractionated)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 79.2 Gy RBE in 44 treatments (standard fractionated)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 26773800

Group type: EXPERIMENTAL
Intervention: Augmentation group (AG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 23446076

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 mcg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diphenhydramine 25 mg
Number of subjects: 11
Study: 22845044

Group type: EXPERIMENTAL
Intervention: BTDS 10 with ketoconazole 200 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: BTDS 10 with placebo
Number of subjects: 20
Study: 20603730

Group type: EXPERIMENTAL
Intervention: Appetite awareness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotional awareness intervention
Number of subjects: 0
Study: 18060958

Group type: EXPERIMENTAL
Intervention: Telephone-administered Pelvic Floor Distress Inventory (PFDI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Telephone-administered Pelvic Floor Impact Questionnaire (PFIQ)
Number of subjects: 55
Study: 15864079

Group type: COMPARATOR
Intervention: Encasings (mattress, pillow and duvet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention tailored to child's sensitization status and home environment
Number of subjects: 0
Study: 12853351

Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2) with carboplatin and paclitaxel
Number of subjects: 187

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel without amifostine
Number of subjects: 187
Study: 10618956

Group type: EXPERIMENTAL
Intervention: nicardipine-PTC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nicardipine-TOF
Number of subjects: 60

Group type: COMPARATOR
Intervention: control-PTC
Number of subjects: 60

Group type: COMPARATOR
Intervention: control-TOF
Number of subjects: 60
Study: 8701411

Group type: EXPERIMENTAL
Intervention: Cyclic transdermal E2 (50 micrograms/day for 21 days) plus medroxyprogesterone acetate (MPA) (10 mg/day from days 10 to 21)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Continuous transdermal E2 (50 micrograms/day for 28 days) plus MPA (10 mg/day from days 14 to 25)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 1906532

Group type: EXPERIMENTAL
Intervention: Gallium nitrate (200 mg/m2/d by continuous IV infusion for 5 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Etidronate (7.5 mg/kg as a 4-hour IV infusion for 5 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Etidronate (7.5 mg/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 71
Study: 6303061

Group type: EXPERIMENTAL
Intervention: Ispaghula granulate before meals
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Bran before meals
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (no fiber preparation)
Number of subjects: 135
Study: 3949943

Group type: EXPERIMENTAL
Intervention: Home measurement monitoring program
Number of subjects: 111
Study: 29523089

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WPS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation and protein supplementation (WB-EMS&P)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100
Study: 27523653

Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrocolloids or foam dressings
Number of subjects: 50
Study: 24754911

Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic canola oil
Number of subjects: 170

Group type: COMPARATOR
Intervention: Other dietary oil blends (canola oil, high oleic canola oil, flax oil, safflower oil blend, corn oil and safflower oil blend)
Number of subjects: 170
Study: 23040656

Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-Thrust Manipulation (NTM)
Number of subjects: 149
Study: 20455879

Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 60 mmHg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 75 mmHg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 90 mmHg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAPs of 60, 75, and 90 mmHg
Number of subjects: 21
Study: 18810296

Group type: EXPERIMENTAL
Intervention: HI PROT (30% of total energy intake; 1.2-1.5 g/kg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LO PROT (15% of total energy intake; 0.5-0.7 g/kg/d)
Number of subjects: 24
Study: 16696931

Group type: EXPERIMENTAL
Intervention: Engagement with hazards in a simulated environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provision of feedback concerning performance
Number of subjects: 0
Study: 12236277

Group type: EXPERIMENTAL
Intervention: Educational outreach visit to primary healthcare teams
Number of subjects: 30
Study: 9725505

Group type: EXPERIMENTAL
Intervention: beta-D-galactosidase pellets (100 u/ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo pellets
Number of subjects: 8
Study: 8017269

Group type: EXPERIMENTAL
Intervention: Multiplane transesophageal echocardiography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biplanar imaging
Number of subjects: 80
Study: 2557219

Group type: EXPERIMENTAL
Intervention: Therapeutic heparinization
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Conventional heparin (high-dose)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Conventional heparin (low-dose)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Any form of heparin therapy
Number of subjects: 181
Study: 1217684

Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg intramuscularly
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doxapram 60 mg intramuscularly
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doxapram 60 mg intramuscularly with Pentazocine 30 mg
Number of subjects: 2
Study: 31775535

Group type: EXPERIMENTAL
Intervention: Magnesium valproate
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 175
Study: 28863886

Group type: COMPARATOR
Intervention: Selective neck dissection (group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Superselective neck dissection (group II)
Number of subjects: 20
Study: 27923343

Group type: EXPERIMENTAL
Intervention: Home tele-management programme delivered by a multidisciplinary health team, involving nurse-tutor telephone support and tele-exercise, followed for 6 months after hospital discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 0
Study: 24323569

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Presence of others smoking
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of all three triggers (alcohol consumption, presence of others smoking, negative affect)
Number of subjects: 300
Study: 22703794

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Collagenase ointment (CO)
Number of subjects: 100
Study: 20188280

Group type: EXPERIMENTAL
Intervention: 2-stage method
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1-stage method
Number of subjects: 50
Study: 17710398

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg single dose on day +5)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Filgrastim (5 microg kg(‐1) day(‐1) starting on day +5)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 44

Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 44
Study: 15516347

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AAI monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 200
Study: 12540388

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFat: > 65% of energy as lipids)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoenergetic high‐carbohydrate diet (HCho: 70‐75% of energy as carbohydrate)
Number of subjects: 14
Study: 10068312

Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy of astrocytomas with borderline histopathological features between WHO grades II and III
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy of astrocytomas with borderline histopathological features between WHO grades III and IV
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group of astrocytic tumors obtained at open surgery
Number of subjects: 156
Study: 7578896

Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 2182917

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic leg compression
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 310